All In Biotech

Drug Trial Radar · NCT01507831

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Long-term Safety and Tolerability of SAR236553 (REGN727) in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study

Last checked: Nov 20, 2026Latest source record: Dec 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,341 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,341

Actual

Start

Jan 2012

Primary completion

Nov 2014

Study completion Nov 2014

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Jan 11, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9). Primary Objective of the study: To evaluate the long-term safety and tolerability of alirocumab in high cardiovascular risk participants with hypercholesterolemia not adequately controlled with their current lipid modifying therapy (LMT). Secondary Objectives: * To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo. * To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points. * To evaluate the effects of alirocumab on other lipid parameters.

Conditions

  • Hypercholesterolemia

Interventions

  • Placebo (for alirocumab)Drug

    Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.

  • AlirocumabDrug

    Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.

  • Lipid-Modifying Therapy (LMT)Drug

    Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced Adverse Events (AEs)Time frame: Up to 10 weeks after last study drug administration (maximum of 86 weeks)

Locations

320 sites in 27 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840159

    Huntsville, Alabama

  • Investigational Site Number 840028

    Gilbert, Arizona

  • Investigational Site Number 840035

    Sierra Vista, Arizona

  • Investigational Site Number 840052

    Tempe, Arizona

  • Investigational Site Number 840065

    Tempe, Arizona

  • Investigational Site Number 840079

    Tempe, Arizona

  • Investigational Site Number 840094

    Tempe, Arizona

  • Investigational Site Number 840103

    Tucson, Arizona

  • Investigational Site Number 840209

    Beverly Hills, California

  • Investigational Site Number 840194

    Beverly Hills, California

  • Investigational Site Number 840207

    Fresno, California

  • Investigational Site Number 840101

    Lincoln, California

  • Investigational Site Number 840076

    Long Beach, California

  • Investigational Site Number 840214

    Pasadena, California

  • Investigational Site Number 840045

    Sacramento, California

  • Investigational Site Number 840163

    Santa Rosa, California

  • Investigational Site Number 840086

    Colorado Springs, Colorado

  • Investigational Site Number 840077

    Golden, Colorado

  • Investigational Site Number 840224

    Bridgeport, Connecticut

  • Investigational Site Number 840134

    Guilford, Connecticut

  • Investigational Site Number 840246

    Hartford, Connecticut

  • Investigational Site Number 840055

    Stamford, Connecticut

  • Investigational Site Number 840091

    Stamford, Connecticut

  • Investigational Site Number 840150

    Atlantis, Florida

  • Investigational Site Number 840020

    Bradenton, Florida

  • Investigational Site Number 840041

    Brandon, Florida

  • Investigational Site Number 840184

    Clearwater, Florida

  • Investigational Site Number 840242

    Clearwater, Florida

  • Investigational Site Number 840039

    Clearwater, Florida

  • Investigational Site Number 840182

    Crystal River, Florida

  • Investigational Site Number 840002

    Daytona Beach, Florida

  • Investigational Site Number 840166

    Daytona Beach, Florida

  • Investigational Site Number 840167

    Fleming Island, Florida

  • Investigational Site Number 840090

    Fort Lauderdale, Florida

  • Investigational Site Number 840018

    Fort Lauderdale, Florida

  • Investigational Site Number 840153

    Jacksonville, Florida

  • Investigational Site Number 840181

    Jacksonville, Florida

  • Investigational Site Number 840152

    Jacksonville, Florida

  • Investigational Site Number 840154

    Lake Mary, Florida

  • Investigational Site Number 840059

    Largo, Florida

Showing 40 of 320 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.